{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T09:46:19Z","timestamp":1793094379004,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004382","name":"WellPoint","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004382","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010544","name":"Exelixis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010544","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015340","name":"Bayer Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015340","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.clgc.2018.08.003","type":"journal-article","created":{"date-parts":[[2018,8,22]],"date-time":"2018-08-22T18:19:54Z","timestamp":1534961994000},"page":"e1237-e1242","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Impact of Neoadjuvant Chemotherapy on Pathologic Response in Patients With Upper Tract Urothelial Carcinoma Undergoing Extirpative Surgery"],"prefix":"10.1016","volume":"16","author":[{"given":"Nima","family":"Almassi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianming","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byron","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georges-Pascal","family":"Haber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshe C.","family":"Ornstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian I.","family":"Rini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy D.","family":"Gilligan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge A.","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Stephenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petros","family":"Grivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2018.08.003_bib1","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.eururo.2006.11.021","article-title":"Transitional cell carcinoma of the ureter: Prognostic factors influencing progression and survival","volume":"51","author":"Lehmann","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2018.08.003_bib2","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/cncr.24135","article-title":"Outcomes of radical nephroureterectomy: a series from the upper tract urothelial carcinoma collaboration","volume":"115","author":"Margulis","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2018.08.003_bib3","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/S0090-4295(98)00295-7","article-title":"Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients","volume":"52","author":"Hall","year":"1998","journal-title":"Urology"},{"key":"10.1016\/j.clgc.2018.08.003_bib4","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2018.08.003_bib5","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.urolonc.2016.11.018","article-title":"Neoadjuvant and adjuvant chemotherapy use in upper tract urothelial carcinoma","volume":"35","author":"Cohen","year":"2017","journal-title":"Urol Oncol"},{"key":"10.1016\/j.clgc.2018.08.003_bib6","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1002\/cncr.25050","article-title":"Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma","volume":"116","author":"Matin","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2018.08.003_bib7","first-page":"68","article-title":"Comparison of pathological stage in patients treated with and without neoadjuvant chemotherapy for high-risk upper tract urothelial carcinoma","volume":"200","author":"Liao","year":"2018","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2018.08.003_bib8","doi-asserted-by":"crossref","first-page":"101500","DOI":"10.18632\/oncotarget.21551","article-title":"Oncological outcomes of neoadjuvant chemotherapy in patients with locally advanced upper tract urothelial carcinoma: a multicenter study","volume":"8","author":"Kubota","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.clgc.2018.08.003_bib9","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cncr.28655","article-title":"Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma","volume":"120","author":"Porten","year":"2014","journal-title":"Cancer"},{"issue":"3 Pt 1","key":"10.1016\/j.clgc.2018.08.003_bib10","first-page":"580","article-title":"Postoperative nomogram for relapse-free survival in patients with high grade upper tract urothelial carcinoma","volume":"197","author":"Krabbe","year":"2017","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2018.08.003_bib11","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1245\/s10434-009-0771-3","article-title":"The National Cancer Database: Past, present, and future","volume":"17","author":"Winchester","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.clgc.2018.08.003_bib13","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.urolonc.2016.11.017","article-title":"Utilization of perioperative systemic chemotherapy in upper tract urothelial carcinoma","volume":"35","author":"Gin","year":"2017","journal-title":"Urol Oncol"},{"key":"10.1016\/j.clgc.2018.08.003_bib14","first-page":"33","article-title":"Diagnostic accuracy of ureteroscopic biopsy in upper tract transitional cell carcinoma","volume":"157","author":"Keeley","year":"1997","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2018.08.003_bib15","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.urology.2011.02.038","article-title":"Inadequacy of biopsy for diagnosis of upper tract urothelial carcinoma: implications for conservative management","volume":"78","author":"Smith","year":"2011","journal-title":"Urology"},{"key":"10.1016\/j.clgc.2018.08.003_bib16","doi-asserted-by":"crossref","first-page":"e879","DOI":"10.1016\/j.clgc.2018.02.002","article-title":"Feasibility of cisplatin-based neoadjuvant chemotherapy in muscle-invasive bladder cancer patients with diminished renal function","volume":"16","author":"Koshkin","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2018.08.003_bib17","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1200\/JCO.2011.34.8433","article-title":"Treatment of patients with metastatic urothelial cancer \u201cunfit\u201d for cisplatin-based chemotherapy","volume":"29","author":"Galsky","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2018.08.003_bib18","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1002\/cncr.25043","article-title":"Chronic kidney disease after nephroureterectomy for upper tract urothelial carcinoma and implications for the administration of perioperative chemotherapy","volume":"116","author":"Lane","year":"2010","journal-title":"Cancer"},{"issue":"suppl 6S","key":"10.1016\/j.clgc.2018.08.003_bib19","article-title":"Results of POUT - a phase III randomized trial of peri-operative chemotherapy versus surveillance in upper tract urothelial carcinoma (UTUC)","volume":"36","author":"Birtle","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2018.08.003_bib20","first-page":"e1166","article-title":"Phase II trial of neoadjuvant chemotherapy followed by extirpative surgery for patients with high grade upper tract urothelial carcinoma (HG UTUC): results from ECOG-ACRIN 8141","volume":"199","author":"Hoffman-Censits","year":"2018","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2018.08.003_bib21","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.eururo.2009.07.002","article-title":"Impact of tumor location on prognosis for patients with upper tract urothelial carcinoma managed by radical nephroureterectomy","volume":"57","author":"Raman","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2018.08.003_bib22","first-page":"453","article-title":"Preoperative multivariable prognostic model for prediction of nonorgan confined urothelial carcinoma of the upper urinary tract","volume":"184","author":"Margulis","year":"2010","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2018.08.003_bib23","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ejca.2011.06.027","article-title":"Racial differences in acute toxicities of neoadjuvant or adjuvant chemotherapy in patients with early-stage breast cancer","volume":"47","author":"Han","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2018.08.003_bib24","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.ajog.2008.04.038","article-title":"Influence of race on tolerance of platinum-based chemotherapy and clinical outcomes in women with advanced and recurrent cervical cancer: a pooled analysis of 3 Gynecologic Oncology Group studies","volume":"199","author":"Plaxe","year":"2008","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.clgc.2018.08.003_bib25","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1200\/JCO.1992.10.7.1066","article-title":"A\u00a0randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study","volume":"10","author":"Loehrer","year":"1992","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2018.08.003_bib26","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1200\/JCO.1990.8.6.1050","article-title":"A\u00a0prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors","volume":"8","author":"Logothetis","year":"1990","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2018.08.003_bib27","article-title":"Platinum-based neoadjuvant chemotherapy improves oncological outcomes in patients with locally advanced upper tract urothelial carcinoma","author":"Hosogoe","year":"2017","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.clgc.2018.08.003_bib28","doi-asserted-by":"crossref","first-page":"e751","DOI":"10.1016\/j.clgc.2018.01.014","article-title":"Prognostic factors and risk stratification in invasive upper tract urothelial carcinoma","volume":"16","author":"Emamekhoo","year":"2018","journal-title":"Clin Genitourin Cancer"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767318303768?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767318303768?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:29:12Z","timestamp":1761564552000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767318303768"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S1558767318303768"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2018.08.003","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Neoadjuvant Chemotherapy on Pathologic Response in Patients With Upper Tract Urothelial Carcinoma Undergoing Extirpative Surgery","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2018.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}